A U.S. study showed that the new 13-valent pneumococcal conjugate vaccine is as safe as the previously used 7-valent pneumococcal conjugate vaccine. Kaiser Permanente researchers compared the number of rare adverse events linked to the new and old vaccines and found that those who received the PCV13 vaccine were no more likely to experience any serious adverse events than those who got the PCV7 vaccine.
Study backs safety of new pneumococcal vaccine
SmartBrief Job Listings for Health Care
|Chief Financial Officer||
B. E. Smith
Attest Health Care Advisors
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|